Poster Abstract Session:
220. Antibacterial Susceptibility Surveillance
Saturday, October 29, 2016: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:

.

Tracks: Adult ID

Presentations:
Comparative In Vitro Activity of Ceftaroline Against Gram-Negative and Gram-Positive Clinically Significant Bacterial Isolates from Patients in a Teaching Hospital.
Vincent Rotimi, MD, PhD, FRCPath, FIDSA ; Wafaa Jamal, MD, PhD, FRCPath ; Hayfaa Abdulkareem, BSc, MSc ; Amal Naji, BSc ; Fatma Al-Failakawy, BSc
In-vitro activity of Ceftaroline and Comparator Agents against Bacterial Isolates from Cancer Patients
Kenneth V. I. Rolston, M.D., FIDSA ; Mohamed Jamal, PhD ; Lior Nesher, MD ; Samuel Shelburne, MD, PhD, FIDSA ; Issam Raad, MD, FIDSA, FSHEA ; Randall Prince, PharmD, FIDSA
Posters
  • Ceftarolline Comparators.pdf (538.3 kB)
  • Trends in Streptococcus pneumoniae Antibiotic Susceptibility at George Washington University Hospital, 2000-2015
    Katherine Dunne, MD candidate 2017 ; Agnes Kresch, MD ; John Keiser, MD ; Marc Siegel, MD
    Posters
  • IDSA 2016 poster final.pdf (677.5 kB)
  • In Vitro Global Surveillance of Eravacycline and Comparators against Staphylococcus spp. and Enterococcus spp. Over a Three-year Period (2013-15)
    Matteo Bassetti, MD, PhD ; Ralph Corey, MD ; Yohei Doi, MD, PhD ; Ian Morrissey, PhD ; Trudy Grossman, PhD ; Melanie Olesky, PhD ; Patrick Scoble, PharmD ; Joyce Sutcliffe, PhD
    Posters
  • 1820_FINAL.pdf (270.9 kB)
  • Activity of Plazomicin and Comparator Agents Tested Against Gram-negative and -positive Clinical Isolates Collected in USA Hospitals During 2015
    Mariana Castanheira, PhD ; Rodrigo E. Mendes, PhD ; Jennifer M. Streit, BS ; Robert K. Flamm, Ph.D.
    Ceftolozane/Tazobactam Activity Tested Against Bacterial Bloodstream Isolates from Multiple Infection Sources
    Leonard R. Duncan, Ph.D. ; Helio S. Sader, MD, PhD ; Robert K. Flamm, Ph.D. ; Mariana Castanheira, PhD
    In Vitro Global Surveillance of Eravacycline and Comparators Against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Including Multidrug-resistant (MDR) Isolates, Over a Three-year Period (2013-15)
    Matteo Bassetti, MD, PhD ; Ralph Corey, MD ; Yohei Doi, MD, PhD ; Ian Morrissey, PhD ; Trudy Grossman, PhD ; Melanie Olesky, PhD ; Patrick Scoble, PharmD ; Joyce Sutcliffe, PhD
    Posters
  • 1825_FINAL.pdf (296.7 kB)
  • S-649266, a Novel Siderophore Cephalosporin: In Vitro Activity against biothreat pathogen
    Masakatsu Tsuji, Ph.D ; Charles Jakielaszek, M.S ; LTC C. L Marchand, D.V.M.
    In Vitro activity of Fosfomycin (ZTI-01, Fosfomycin for Injection) Against Contemporary Gram-negative and Gram-positive Isolates- a Comparison of Inter-Method Testing
    Robert K. Flamm, Ph.D. ; Paul R. Rhomberg, BS ; Holly K. Huynh, BS ; Helio S. Sader, MD, PhD ; E. J. Ellis-Grosse, PhD
    Posters
  • IDWeek16 Fosfomycin 1833.pdf (492.3 kB)
  • Dalbavancin In Vitro Activity Obtained Against Gram-positive Clinical Isolates Causing Osteomyelitis in USA Hospitals (2011 - 2015)
    Rodrigo E. Mendes, PhD ; Robert K. Flamm, Ph.D. ; Michael Pfaller, MD, FIDSA ; Mariana Castanheira, PhD ; Helio S. Sader, MD, PhD
    Posters
  • IDWeek16 Dalbavancin 1834.pdf (431.1 kB)
  • Activity of Dalbavancin Tested Against Gram-positive Clinical Isolates Causing Skin and Skin Structure Infections in Pediatric Patients from USA Hospitals (2014 - 2015).
    Rodrigo E. Mendes, PhD ; Helio S. Sader, MD, PhD ; Michael Pfaller, MD, FIDSA ; Mariana Castanheira, PhD ; Robert K. Flamm, Ph.D.
    Posters
  • IDWeek16 Dalbavancin 1835.pdf (245.8 kB)
  • A 2012-2014 Global Antimicrobial Surveillance of Iclaprim Against Clinical Strains Causing Hospital-Associated Bacterial Pneumonia (HABP) and Skin and Skin Structure Infections (SSSI)
    David Huang, MD, PhD ; Thomas M. File Jr., MD, MSc, MACP, FIDSA, FCCP ; Mark Wilcox, MD ; Matthew Dryden, MD ; G Corey, MD ; Rajesh Shukla, PhD
    Posters
  • Poster 1836-final.pdf (443.8 kB)
  • Assessment of Patients with Amp-C Inducible Enterobacteriaceae with Susceptibility Changes During Therapy
    Meghan Jeffres, PharmD ; Clayton Foster, MD ; Bruce Mccollister, MD ; Randolph Fujit, PharmD ; Mary Bessesen, MD ; Michelle Barron, MD
    "Telavancin displays activity against Cystic Fibrosis-associated MRSA strains including those with increased resistance to Ceftaroline"
    Melanie Roch, PharmD ; Maria Pilar Martinez, Ph.D ; Maryam Fatouraei, BS ; Warren Rose, PharmD ; Rafael Hernandez, MD/PhD ; Lucas Hoffman, MD; PhD ; Ian Yun, PharmD ; Wesley Long, MD; Ph.D ; Adriana E Rosato, MS; Ph.D
    Antimicrobial Susceptibility Profiles of Key Intra-abdominal (IAI) Bacterial Isolates from North America: 2011-2015
    Douglas Biedenbach, MS ; Martha Renteria, MD ; Heidi Leister-Tebbe, BSN ; Dan Sahm, PhD
    Antimicrobial Susceptibility of KPC-producing Enterobacteriaceae Stratified by Infection Site (USA, 2012-2015)
    Mariana Castanheira, PhD ; Rodrigo E. Mendes, PhD ; Robert K. Flamm, Ph.D. ; Helio S. Sader, MD, PhD
    Posters
  • IDWeek16 CAZ-AVI KPC 1850.pdf (232.0 kB)
  • The susceptibility of Eravacycline and Comparators to Global Isolates of Acinetobacter baumannii
    Harald Seifert, MD ; Danuta Stefanik, BS ; Paul Higgins, PhD ; Joyce Sutcliffe, PhD

    CME Credits: No CME credit is offered for this session.

    ACPE Credits:

    ACPE Number:


    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.